The Future of Remote Patient Monitoring in 2026

Remote patient monitoring has moved well beyond the early-adopter phase. Reimbursement pathways are established, device ecosystems are maturing, and clinical evidence continues to stack up in favor of continuous monitoring over episodic visits. But the RPM market heading into 2026 looks meaningfully different from what practices implemented even two years ago.

This post covers what’s actually changing in RPM heading into 2026 and what each shift means for primary care practices running or planning programs today.

AI and Machine Learning Are Moving From Buzzword to Billing Justification

The earliest RPM programs were essentially data pipelines: a device transmitted a reading, a dashboard displayed it, and a clinician reviewed it. That model works, but it does not scale. A practice managing 200 RPM patients generates thousands of data points per week, and most of those readings fall within normal ranges.

AI and machine learning are solving this signal-to-noise problem. Predictive algorithms now flag patients whose glucose trends suggest an impending A1C increase weeks before it shows up in lab work. Pattern recognition models identify medication non-adherence from transmission gaps without requiring the patient to self-report.

What This Means for Primary Care

The practical impact is twofold. First, clinical staff spend less time reviewing unremarkable data and more time intervening where it matters. Second, AI-generated risk scores are beginning to serve as documentation support for the clinical decision-making required under CPT 99457 and 99458; the interactive communication codes that require real-time clinical judgment.

Practices that adopt AI-assisted RPM platforms will have an edge in both efficiency and compliance documentation.

Payer Coverage Is Expanding Beyond Medicare

Medicare has been the dominant payer for RPM since CMS formalized the billing codes in 2019. But commercial payer coverage is shifting rapidly. UnitedHealthcare, Aetna, and Anthem have all introduced RPM reimbursement pathways for specific chronic conditions, and several state Medicaid programs (including Texas, California, and New York) now cover RPM services for qualifying populations.

Payer Category	RPM Coverage Status (2025-2026)	Key Conditions Covered
Medicare (Traditional)	Full coverage, CPT 99453-99458	All qualifying chronic conditions
Medicare Advantage	Varies by plan; majority now cover	Diabetes, hypertension, CHF
Commercial (Major Nationals)	Growing adoption; prior auth common	Diabetes, hypertension, COPD
State Medicaid	18+ states with active coverage	High-risk pregnancy, diabetes
Employer Self-Funded Plans	Emerging; tied to wellness programs	Diabetes, musculoskeletal

The Revenue Implication

For primary care practices that currently bill RPM only to Medicare, the expansion to commercial payers opens a larger eligible patient pool. A practice with 600 diabetic patients where 40% are commercially insured could see its addressable RPM population nearly double as commercial coverage solidifies.

The challenge is that commercial payer requirements often differ from Medicare’s. Transmission day minimums, eligible device types, and prior authorization workflows vary by plan. Practices need billing infrastructure that can handle payer-specific rules rather than applying a single Medicare-based template to every claim.

CMS Policy Is Tightening Compliance While Broadening Access

CMS has signaled two parallel policy directions that may seem contradictory but are actually complementary.

On one hand, CMS is expanding the conditions and care settings eligible for RPM reimbursement. The 2025 Physician Fee Schedule finalized rules that clarify RPM applicability in federally qualified health centers and rural health clinics, populations that historically had limited access.

On the other hand, CMS is increasing audit scrutiny on RPM claims. The Office of Inspector General flagged RPM billing as a focus area for 2025-2026 audits, specifically targeting practices that bill 99457/99458 without adequate documentation of interactive communication, and practices that bill 99454 for patients who do not meet the 16-day transmission threshold.

Key takeaway: The window for loosely documented RPM billing is closing. Practices that invest in rigorous, automated compliance tracking now will be positioned to scale their programs as CMS broadens access, while practices relying on manual tracking face increasing audit risk.

What to Watch

The proposed 2026 Physician Fee Schedule is expected to address two open questions: whether CMS will adjust the 16-day transmission requirement and whether RPM-specific quality measures will be introduced into MIPS reporting. Both would have significant operational impact on how practices structure their programs.

Wearable Devices Are Getting Clinically Serious

Consumer wearables and clinical-grade RPM devices have historically occupied different worlds. Fitbits and Apple Watches tracked steps and heart rate for wellness; FDA-cleared glucometers and blood pressure cuffs generated the data required for reimbursable RPM.

Those two categories are converging. Continuous glucose monitors like the Dexcom G7 and Abbott FreeStyle Libre 3 now offer both consumer and clinical-grade data streams from the same device. Apple Watch Series 10 received FDA clearance for atrial fibrillation detection that meets the evidentiary bar for clinical decision-making.

RPM-Eligible Devices in 2026

Device Category	Clinical Maturity	RPM Billing Eligibility	Cost Trend
Blood glucose meters (traditional)	High	Fully eligible	Stable ($20-40/unit)
Continuous glucose monitors	High	Eligible with clinical-grade firmware	Declining ($50-75/month)
Connected blood pressure cuffs	High	Fully eligible	Declining ($30-60/unit)
Smartwatch-based vitals	Moderate	Limited; payer-dependent	Stable ($250-400/unit)
Wearable ECG/arrhythmia patches	High	Eligible for specific conditions	Declining ($100-200/month)
Smart scales (CHF monitoring)	Moderate-High	Eligible for CHF populations	Stable ($40-80/unit)

For primary care practices focused on diabetic populations, the convergence of CGMs and RPM billing creates an opportunity to offer patients a better monitoring experience while generating more granular clinical data. The key constraint remains ensuring that the device and data pathway meet CMS requirements for a qualifying RPM device: data must be automatically transmitted to the practice without requiring patient-initiated uploads.

Interoperability Mandates Are Forcing Data Integration

The 21st Century Cures Act and subsequent ONC rules have been pushing healthcare toward open APIs and standardized data exchange for years. RPM data is now covered by these requirements.

Starting in 2025, EHR vendors certified under ONC criteria must support FHIR-based APIs for patient-generated health data, which includes RPM device readings. This means RPM platforms that previously existed as standalone dashboards are increasingly expected to feed data directly into the clinical record through standardized interfaces.

Why This Matters Operationally

For practices, interoperability reduces the dual-documentation burden that has plagued RPM programs. When glucose readings flow automatically from the RPM platform into the EHR, the clinician’s review and response are documented in context, alongside medication lists, lab results, and visit notes. This creates a more defensible audit trail and reduces the time staff spend manually reconciling data between systems.

Practices evaluating RPM platforms in 2026 should prioritize vendors with certified FHIR integrations for their specific EHR. A platform that works well in isolation but requires manual data entry into the clinical record is a compliance liability and an operational drag.

Market Growth Is Accelerating; Consolidation Is Coming

The RPM market is projected to reach $175 billion globally by 2028, growing at a compound annual rate above 25%. In the U.S., the addressable market for RPM in primary care alone is estimated at $12-15 billion based on the chronic disease population eligible for reimbursable monitoring.

Venture funding into RPM-focused companies exceeded $2.8 billion in 2024, and the first wave of acquisitions is underway as larger health IT companies acquire point solutions to build integrated chronic care platforms.

What Consolidation Means for Practices

When vendors consolidate, practices face two risks: platform lock-in and feature deprioritization. A small RPM vendor that gets acquired by a large EHR company may shift its roadmap to serve the acquirer’s strategic priorities rather than the needs of independent practices.

The mitigation is to choose RPM partners whose core value proposition aligns with what your practice actually needs: compliance automation, billing accuracy, and clinical workflow integration. A long feature list matters less than whether the platform solves the problems you have today.

The Shift From Volume to Value Is Accelerating RPM Adoption

Value-based care arrangements are no longer limited to large health systems. CMS’s Making Care Primary model, launching in 2025 across eight states, brings primary care practices into prospective payment arrangements that explicitly reward chronic disease management and care coordination, which is exactly what RPM supports.

Under these models, RPM is not just a fee-for-service revenue stream. It becomes a cost-avoidance tool. Every diabetic patient whose A1C stays controlled through continuous monitoring is a patient who avoids the emergency department visit, the inpatient admission, and the specialist referral that erode margins under capitated payment.

Looking ahead: Practices participating in value-based arrangements should model RPM’s impact on total cost of care, not just its per-patient reimbursement. The financial case for RPM under capitation is often stronger than under fee-for-service, even before accounting for billing revenue.

What This Means for Your Practice in 2026

The core RPM model (devices transmit data, clinicians act on it, payers reimburse for the service) is not changing. What is changing is every layer around it: smarter analytics, broader coverage, tighter compliance expectations, better devices, and deeper integration with the clinical record.

For primary care practices serving diabetic populations, the direction is clear: invest in RPM infrastructure that automates compliance, handles multi-payer billing requirements, and integrates with your clinical workflow. The programs that thrive in 2026 will be the ones that treat RPM as a core clinical service rather than a billing add-on.

Zayd Health is designed around this idea. We automate compliance tracking and billing so that clinical teams can focus on what RPM is actually for: better outcomes for patients with chronic conditions. If you are building or scaling an RPM program, see how it works.